Stockscreener 앱 받기
2.57
4.81%
-0.13
시간 외 거래:
2.64
0.07
+2.72%
전일 마감가:
$2.70
열려 있는:
$2.67
하루 거래량:
586.12K
Relative Volume:
0.79
시가총액:
$190.77M
수익:
$6.96M
순이익/손실:
$-46.51M
주가수익비율:
-14.98
EPS:
-0.1716
순현금흐름:
$-37.99M
1주 성능:
+7.53%
1개월 성능:
+6.64%
6개월 성능:
-40.92%
1년 성능:
-80.53%
1일 변동 폭
$2.525
$2.77
1주일 범위
$2.34
$2.77
52주 변동 폭
$1.60
$16.55
Perspective Therapeutics Inc Stock (CATX) Company Profile
명칭
Perspective Therapeutics Inc
전화
509-375-1202
주소
350 Hills Street, Suite 106, Richland
CATX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
2.57 | 177.41M | 6.96M | -46.51M | -37.99M | -0.1716 |
|
ABT
Abbott Laboratories
|
133.58 | 228.44B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
105.26 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.64 | 143.93B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
82.98 | 103.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.22 | 43.99B | 5.54B | 4.18B | 623.10M | 7.00 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | H.C. Wainwright | Buy |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-11-25 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-01 | 개시 | Wedbush | Outperform |
| 2024-09-25 | 개시 | Truist | Buy |
| 2024-07-25 | 개시 | BofA Securities | Buy |
| 2024-05-09 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Perspective Therapeutics Inc 주식(CATX)의 최신 뉴스
Perspective Therapeutics, Inc. (CATX) Reports Positive Results for NET Treatment Trial - Insider Monkey
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-?-NET at the 2025 ASCO Annual Meeting | CATX Stock News - GuruFocus
Perspective Therapeutics Provides Updated Interim Results and Safety Findings for [212Pb]VMT-α-NET at ASCO 2025 - Nasdaq
Perspective Therapeutics Highlights Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting - Yahoo Finance
Millennium Management LLC Buys New Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Neuroendocrine Tumors Market: Epidemiology, Therapies, - openPR.com
Perspective Therapeutics Holds Annual Stockholders Meeting - TipRanks
Perspective Therapeutics Announces Voting Results - Investing.com
Northern Trust Corp Acquires 13,115 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Janus Henderson Group PLC Has $57,000 Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of “Buy” by Brokerages - Defense World
Equities Analysts Offer Predictions for CATX Q1 Earnings - Defense World
HC Wainwright Has Pessimistic Outlook of CATX Q3 Earnings - Defense World
Perspective Therapeutics, Inc. (CATX): Analysts See 460% Upside Potential - MSN
Head-To-Head Review: Avinger (NASDAQ:AVGR) and Perspective Therapeutics (NYSE:CATX) - Defense World
Perspective Therapeutics’ SWOT analysis: rare disease stock faces clinical hurdles - Investing.com Nigeria
Mercer Global Advisors Inc. ADV Invests $51,000 in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics Reports Q1 2025 Earnings - TipRanks
Perspective Therapeutics (CATX) Rating Maintained, Price Target Lowered | CATX Stock News - GuruFocus
Truist Securities Adjusts Perspective Therapeutics Price Target to $8 From $10, Maintains Buy Rating - marketscreener.com
Oppenheimer cuts CATX stock price target to $15, maintains Outperform By Investing.com - Investing.com South Africa
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results | CATX Stock News - GuruFocus
Oppenheimer Trims Perspective Therapeutics Price Target to $15 From $16, Maintains Outperform Rating - marketscreener.com
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Wells Fargo & Company MN - Defense World
Oppenheimer cuts CATX stock price target to $15, maintains Outperform - Investing.com
Perspective Therapeutics: Q1 Earnings Snapshot - The Washington Post
Perspective Therapeutics Inc (CATX) Q1 2025 Earnings: EPS Loss of $0.25 Beats Estimate, Revenue of $0.3M Exceeds Expectations - GuruFocus
Perspective Therapeutics Reports Q1 2025 Results and Updates - TipRanks
Perspective Therapeutics Provides Recent Business Highlights and Reports 1Q 2025 Results - The Manila Times
Perspective Therapeutics, Inc. Announces Clinical Updates and Recruitment Progress for Novel Radiopharmaceuticals Ahead of 2025 ASCO Meeting - Nasdaq
Perspective Therapeutics (CATX) Prepares for Q1 Earnings Announcement - GuruFocus
Perspective Therapeutics, Inc. (NYSE:CATX) Shares Sold by Barclays PLC - Defense World
Mariner LLC Invests $150,000 in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics Inc (AMEX: CATX): Down -84.76% In 2025, Outlook Remains Negative - Stocksregister
Legal & General Group Plc Has $155,000 Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics to Participate in Upcoming May Investor Conferences - The Manila Times
JPMorgan Chase & Co. Boosts Stock Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World
Perspective Therapeutics Treats First Patient in Phase 1/2a Trial for Solid Tumors - marketscreener.com
Perspective Therapeutics (CATX) Launches Initial Patient Treatme - GuruFocus
Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors - The Manila Times
Groundbreaking Cancer Treatment Trial Launches: Perspective's FAP-α Targeted Alpha Therapy Shows Promise - Stock Titan
Perspective Therapeutics, Inc. (NYSE:CATX) Given Average Recommendation of “Buy” by Brokerages - Defense World
A History of Outperforming Analyst Forecasts and Beating the Odds: Perspective Therapeutics Inc (CATX) - Sete News
A company insider recently bought 22,026 shares of Perspective Therapeutics Inc [CATX]. Should You Buy? - knoxdaily.com
Perspective Therapeutics Inc (CATX)’s stock rises to 2.33 per share - uspostnews.com
Perspective Therapeutics Announces Acceptance of VMT-?-NET and V - GuruFocus
Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting - The Manila Times
Perspective Therapeutics Announces Acceptance of Key Radiopharmaceutical Data for Presentation at ASCO 2025 Annual Meeting - Nasdaq
Major Breakthrough: Perspective Therapeutics to Present Novel Cancer Treatment Data at ASCO 2025 - Stock Titan
CATX Stock on the Rise: A Promising Investment - investchronicle.com
Truist Financial Sticks to Their Buy Rating for Perspective Therapeutics (CATX) - The Globe and Mail
Perspective Therapeutics Inc (CATX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.38%
자본화:
|
볼륨(24시간):